within Pharmacolibrary.Drugs.ATC.V;

model V03AC03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 9.999999999999999e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0144,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 19.8,            
    Vdp             = 0.0066,
    k12             = 4.6,
    k21             = 4.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AC03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Deferasirox is an oral iron chelator used for the treatment of chronic iron overload due to blood transfusions in patients with conditions such as thalassemia, sickle cell disease, and other chronic anemias. It is approved for clinical use and is currently available in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration in adult patients with transfusional iron overload. Values reflect a typical population (mean age ~27 years, both sexes) receiving once-daily dosing.</p><h4>References</h4><ol><li><p>Vanorden, HE, &amp; Hagemann, TM (2006). Deferasirox--an oral agent for chronic iron overload. <i>The Annals of pharmacotherapy</i> 40(6) 1110–1117. DOI:<a href=\"https://doi.org/10.1345/aph.1G566\">10.1345/aph.1G566</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16735647/\">https://pubmed.ncbi.nlm.nih.gov/16735647</a></p></li><li><p>Tanaka, C (2014). Clinical pharmacology of deferasirox. <i>Clinical pharmacokinetics</i> 53(8) 679–694. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0151-4\">10.1007/s40262-014-0151-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24996374/\">https://pubmed.ncbi.nlm.nih.gov/24996374</a></p></li><li><p>Galanello, R, et al., &amp; Origa, R (2012). Deferasirox: pharmacokinetics and clinical experience. <i>Expert opinion on drug metabolism &amp; toxicology</i> 8(1) 123–134. DOI:<a href=\"https://doi.org/10.1517/17425255.2012.640674\">10.1517/17425255.2012.640674</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22176640/\">https://pubmed.ncbi.nlm.nih.gov/22176640</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AC03;
